| abstract |
The present invention is related to novel polysaccharide – protein conjugate vaccine formulation comprising of at least one of Neisseria meningitidis serogroup A, C, Y, W or X synthetic oligosaccharides (Men A, C, Y, W, X), each said oligosaccharide (OS) being conjugated separately to carrier protein., either none or at least one but not exceeding four bacterial capsular polysaccharide (PS) of Men A, C, Y, W or X, each said polysaccharide being conjugated separately to carrier protein, one or more buffer along with pharmaceutically acceptable components/excipients, with or without an adjuvant. The formulation is a mono- or bi- or multi-valent, liquid or lyophilized or a Liquid-Lyo combination formulation providing desired osmolality, desired pH, high stability and desired immunogenicity. |